Specialty pharmaceutical firm Watson Pharmaceuticals, Inc. (WPI: News ) Friday provided earnings and revenue outlook for fiscal 2011 during an investor meeting held in New York. The company also announced its earnings growth forecast for the long term and detailed on the pipeline developments within its Global Generics and Global Brands businesses.
According to the company's president and chief executive officer Paul Bisaro, 2010 was a successful year with a 25 percent rise in total net revenues and a 12 percent growth in adjusted cash earnings per share.
"In addition to delivering continued strong results, we fully integrated our commercial generic operations in key global markets and further expanded into high growth emerging markets. We successfully expanded our Global Generics and Global Brands product pipelines and initiated our first biologic development project," Bisaro noted.
For fiscal 2010, the company's Global Generics revenue is expected to be $2.35 billion while Global Brands revenue is estimated to be $400 million. The company also forecasts Anda Distribution revenue of approximately $830 million for the full-year 2010.
Watson is set to announce its fourth-quarter and fiscal 2010 results on February 15.